North America Molecular Diagnostics Market Share, Industry Growth And Overview To 2024: Hexa Reports
The North America molecular diagnostics market is expected to reach over USD 7.2 billion by 2024, according to a new report by Grand View Research, Inc.
The North America molecular diagnostics market is expected to reach over USD 7.2 billion by 2024, according to a new report by Grand View Research, Inc.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Hexa</strong> <strong>Reports</strong><br />
<strong>Market</strong> Research <strong>Reports</strong> and Insightful Company Profiles<br />
<strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Analysis,<br />
<strong>Share</strong> and Size, Trends, <strong>Industry</strong> <strong>Growth</strong>, <strong>Overview</strong> <strong>And</strong><br />
Segment Forecasts <strong>To</strong> <strong>2024</strong><br />
The <strong>North</strong> <strong>America</strong> molecular diagnostics market is expected to reach over USD 7.2 billion by <strong>2024</strong>,<br />
according to a new report by Grand View Research, Inc. As a developed economy, <strong>North</strong> <strong>America</strong> has a<br />
well-equipped healthcare infrastructure. Moreover, the U.S. healthcare expenditure is projected to<br />
increase at a substantial rate over the forecast period.<br />
Technological advancement in molecular diagnostic kits is expected to serve the as a primary driving<br />
force. Extensive R&D activities undertaken by the major companies for expansion of their product<br />
portfolio is another factor supporting growth. For instance, in 2015, a strategic collaboration was made<br />
between Sysmex Corporation and Laboratory Corporation in the field of blood-based molecular<br />
diagnostic tests to develop precision medicine in oncology.<br />
Browse Detail Report With TOC @<br />
http://www.hexareports.com/report/north-america-molecular-diagnostics-market/details<br />
Further key findings from the report suggest:<br />
Reagents dominated the molecular diagnostics market with revenue of over USD 1.0 billion in 2015,<br />
owing to increasing R&D initiatives and as a result of discovery of novel biomarkers for cancer.<br />
Moreover, the fastest growing segment over the forecast period is also expected to be reagents, due to<br />
increasing adoption in the process of drug discovery.
<strong>Hexa</strong> <strong>Reports</strong><br />
<strong>Market</strong> Research <strong>Reports</strong> and Insightful Company Profiles<br />
In 2015, the largest shareholder by test location was central laboratories with around 60.0% share. The<br />
key attributes included expansion of healthcare facilities and presence of multiple clinical laboratory<br />
assays.<br />
However, the point-of-care (PoC) segment is estimated to witness the most lucrative growth over the<br />
forecast period owing to development of fast and accurate diagnostic devices.<br />
Infectious diseases contributed to the largest market revenue in 2015, as a result of new product<br />
development in the field of blood screening tests. HIV served as the largest market share rendering<br />
segment among infectious diseases.<br />
The oncology segment is expected to grow at a lucrative double digit CAGR in the forecast period. This<br />
results from the high prevalence of cancer and greater opportunities in the field of cancer diagnostic<br />
tests for major players in <strong>North</strong> <strong>America</strong>.<br />
On the basis of technology, polymerase chain reaction (PCR) dominated the market with USD 1.2 billion<br />
in 2015, owing to increasing applications of PCR in cancer tests<br />
Request A Sample copy of This Report @ http://www.hexareports.com/sample/159391<br />
Sequencing is anticipated to be the fastest growing technology over the forecast period due to<br />
introduction of cost-effective and quick next-generation sequencing platforms for genetic diseases,<br />
cancer, and other chronic disorders.<br />
The U.S. held the major share of the market in 2015 attributable to its developed economy and greater<br />
level of awareness amongst the population.<br />
However, Canada is estimated to exhibit the fastest growth in terms of CAGR, owing to increasing<br />
prevalence of lifestyle diseases, such as cardiovascular diseases.<br />
Some key players in the market include Abbott Laboratories; Roche <strong>Diagnostics</strong>; Hologic, Inc. (Gen<br />
Probe); Novartis AG; Bio-Rad laboratories, Inc.; Cepheid; Siemens Healthineers GmbH; Johnson &<br />
Johnson Services, Inc.; Bayer AG; Alere; bioMerieux SA; Sysmex Corporation; Becton, Dickinson and<br />
Company (BD); Danaher Corporation; Dako; and QIAGEN.<br />
The strategies implemented by the participants include innovations through introduction of devices<br />
providing quick test results of blood samples and expansion to emerging markets.<br />
Table Of Content<br />
Chapter 1 Executive Summary
<strong>Hexa</strong> <strong>Reports</strong><br />
<strong>Market</strong> Research <strong>Reports</strong> and Insightful Company Profiles<br />
Chapter 2 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> - <strong>Industry</strong> Outlook<br />
2.1 Introduction<br />
2.2 <strong>Market</strong> Segmentation<br />
2.3 <strong>Market</strong> Size and <strong>Growth</strong> Prospects<br />
2.4 <strong>Molecular</strong> <strong>Diagnostics</strong> - <strong>Market</strong> dynamics<br />
2.5 Key Opportunities Prioritized<br />
2.6 <strong>Molecular</strong> <strong>Diagnostics</strong> - PESTEL Analysis<br />
2.7 <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> - Company <strong>Market</strong> <strong>Share</strong> Analysis, 2013<br />
Chapter 3 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> Product Outlook<br />
3.1 <strong>Molecular</strong> <strong>Diagnostics</strong> Revenue <strong>Share</strong> by Product, 2013 & <strong>2024</strong><br />
3.2 <strong>Molecular</strong> Diagnostic Instruments <strong>Market</strong><br />
3.3 <strong>Molecular</strong> Diagnostic Reagents <strong>Market</strong><br />
3.4 Others<br />
Healthcare <strong>Market</strong> Research Related <strong>Reports</strong>:<br />
Tuberculosis <strong>Diagnostics</strong> <strong>Market</strong> Size <strong>And</strong> Forecast <strong>And</strong> Trend Analysis From 2013 to <strong>2024</strong> -<br />
http://www.hexareports.com/report/tuberculosis-diagnostics-market/details<br />
Biosimulation <strong>Market</strong> Analysis <strong>And</strong> Segment Forecasts <strong>To</strong> <strong>2024</strong> -<br />
http://www.hexareports.com/report/biosimulation-market/details<br />
Chapter 4 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> Test Location Outlook<br />
4.1 <strong>Molecular</strong> <strong>Diagnostics</strong> Revenue <strong>Share</strong> by Test Location, 2013 & <strong>2024</strong><br />
4.2 <strong>Molecular</strong> Diagnostic Point-of-Care <strong>Market</strong><br />
4.3 <strong>Molecular</strong> <strong>Diagnostics</strong> Self-Test or OTC <strong>Market</strong><br />
4.4 <strong>Molecular</strong> Diagnostic Central Laboratories <strong>Market</strong><br />
Chapter 5 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> Technology Outlook<br />
5.1 <strong>Molecular</strong> <strong>Diagnostics</strong> Revenue <strong>Share</strong> by Technology, 2013 & <strong>2024</strong><br />
5.2 <strong>Molecular</strong> <strong>Diagnostics</strong> Polymerase Chain Reaction (PCR) <strong>Market</strong><br />
5.3 <strong>Molecular</strong> <strong>Diagnostics</strong> In-situ Hybridization <strong>Market</strong><br />
5.4 <strong>Molecular</strong> <strong>Diagnostics</strong> Isothermal Nucleic Acid Amplification Technology (INAAT) <strong>Market</strong><br />
5.5 <strong>Molecular</strong> <strong>Diagnostics</strong> Chips and Microarrays <strong>Market</strong><br />
5.6 <strong>Molecular</strong> DIAGNOSTICS MASS SPECTROMETRY (MS) <strong>Market</strong><br />
5.7 <strong>Molecular</strong> Diagnostic Sequencing <strong>Market</strong><br />
5.8 <strong>Molecular</strong> <strong>Diagnostics</strong> Transcription Mediated Amplification (TMA) <strong>Market</strong><br />
5.9 <strong>Molecular</strong> Diagnostic Other Technology Segments <strong>Market</strong>
<strong>Hexa</strong> <strong>Reports</strong><br />
<strong>Market</strong> Research <strong>Reports</strong> and Insightful Company Profiles<br />
Chapter 6 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> Application Outlook<br />
6.1 <strong>Molecular</strong> <strong>Diagnostics</strong> Revenue <strong>Share</strong>, by Application, 2013 & <strong>2024</strong><br />
6.2 <strong>Molecular</strong> <strong>Diagnostics</strong>-based Oncology <strong>Market</strong><br />
6.3 <strong>Molecular</strong> Diagnostic-based Pharmacogenomics <strong>Market</strong><br />
6.4 <strong>Molecular</strong> <strong>Diagnostics</strong>-based Infectious Diseases <strong>Market</strong><br />
6.5 <strong>Molecular</strong> <strong>Diagnostics</strong>-based Genetic Testing <strong>Market</strong><br />
6.6 <strong>Molecular</strong> <strong>Diagnostics</strong>-based Neurological Diseases <strong>Market</strong><br />
6.7 <strong>Molecular</strong> <strong>Diagnostics</strong>-based Cardiovascular Diseases <strong>Market</strong><br />
6.8 <strong>Molecular</strong> <strong>Diagnostics</strong>-Microbiology <strong>Market</strong><br />
6.9 <strong>Molecular</strong> <strong>Diagnostics</strong> in Other Application Segments <strong>Market</strong><br />
Chapter 7 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> Regional Outlook<br />
7.1 <strong>North</strong> <strong>America</strong> <strong>Molecular</strong> <strong>Diagnostics</strong> Revenue <strong>Share</strong> by Region, 2013 & <strong>2024</strong><br />
7.2 U.S.<br />
7.3 Canada<br />
Chapter 8 Competitive Landscape<br />
8.1 Abbott Laboratories<br />
8.2 Alere<br />
8.3 Bayer AG<br />
8.4 BD<br />
8.5 bioMérieux SA<br />
8.6 Bio-Rad Laboratories ?<br />
8.7 Cepheid<br />
8.8 Dako<br />
8.9 Danaher Corporation<br />
8.10 Hologic, Inc. (Gen Probe)<br />
Chapter 9 Methodology and Scope<br />
9.1 Research Methodology<br />
9.2 Research Scope & Assumptions<br />
9.3 List of Data Sources<br />
Browse Full Report @<br />
http://www.hexareports.com/report/north-america-molecular-diagnostics-market/details<br />
About Us:<br />
<strong>Hexa</strong> <strong>Reports</strong> is a market research and consulting organization, offering industry reports, custom<br />
research and consulting services to a host of key industries across the globe. We offer comprehensive
<strong>Hexa</strong> <strong>Reports</strong><br />
<strong>Market</strong> Research <strong>Reports</strong> and Insightful Company Profiles<br />
business intelligence in the form of industry reports which help our clients obtain clarity about their<br />
business environment and enable them to undertake strategic growth initiatives.<br />
Contact Information:<br />
Ryan Shaw<br />
Felton Office Plaza,<br />
6265 Highway 9,<br />
Felton, California, 95018,<br />
United States<br />
Phone Number<br />
1-800-489-3075<br />
Email Us: sales@hexareports.com<br />
Our Website: http://www.hexareports.com/<br />
Visit our Blog: http://hexareports.blogspot.com/<br />
Like our Facebook page: https://www.facebook.com/hexareportsindustry/<br />
Follow us on LinkedIn: https://www.linkedin.com/company/hexa-reports-inc-
Change language